Source link : https://www.newshealth.biz/health-news/triple-therapy-in-metastatic-crc-with-braf-mutations-the-new-standard-of-care/
SAN FRANCISCO — First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER trial. The study looked at encorafenib (Braftovi) and cetuximab (Erbitux) plus mFOLFOX6 chemotherapy (EC-FOLFOX6) versus standard of care (SOC), and demonstrated a 60.9% overall response rate with EC-FOLFOX6 versus 40% […]
Author : News Health
Publish date : 2025-01-26 21:30:00
Copyright for syndicated content belongs to the linked Source.